Evidence map›Paper›PMID 42797586›Full record

ArticleVaccines2026

The African Polio Laboratory Network: Advancing Regional Poliovirus Detection, Genomic Surveillance, and Eradication.

Brook Tesfaye, Terna Nomhwange, Shelina Moonsamy, Julius E Chia, Maryceline M Baba, Adedayo Omotayo Fanaye, Mesfin Tefera, Yogolelo Riziki, Peter Borus, Josephine Bwogi and 9 more

Abstract read
In one paragraph

Article in Vaccines, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Brook TesfayePolio Eradication Program, Office of the Regional Director, World Health Organization, Regional Office for Africa, Brazzaville P.O. Box 06, Congo.ORCID 0000-0001-8426-3788
Terna NomhwangePolio Eradication Program, Office of the Regional Director, World Health Organization, Regional Office for Africa, Brazzaville P.O. Box 06, Congo.ORCID 0000-0002-1563-4351
Shelina MoonsamyCentre for Vaccines and Immunology, National Institute for Communicable Diseases, a Division of the National Health Laboratory Service, Johannesburg 2192, South Africa.ORCID 0000-0002-8490-8977
Julius E ChiaPolio Eradication Program, Office of the Regional Director, World Health Organization, Regional Office for Africa, Brazzaville P.O. Box 06, Congo.
Maryceline M BabaDepartment of Medical Laboratory Science, College of Medical Sciences, University of Maiduguri, Maiduguri 600004, Nigeria.ORCID 0000-0002-1004-1717
Adedayo Omotayo FanayeDepartment of Virology, College of Medicine, Faculty of Clinical Sciences, University Ibadan, Ibadan 200005, Nigeria.ORCID 0000-0001-6163-286X
Mesfin TeferaEthiopian Public Health Institute, Addis Ababa 1000, Ethiopia.
Yogolelo RizikiInstitute National de Recherche Biomédicale, Kinshasa 5345, Democratic Republic of the Congo.
Peter BorusWorld Health Organization, Nairobi 00100, Kenya.
Josephine BwogiEPI Laboratory, Uganda Virus Research Institute, Entebbe P.O. Box 49, Uganda.ORCID 0000-0001-6975-7106
Marie-Claire EndegueService de Virologie, Centre Pasteur du Cameroun, Yaoundé 1274, Cameroon.ORCID 0000-0001-7494-8628
Mariette GlithoPolio Eradication Program, Office of the Regional Director, World Health Organization, Regional Office for Africa, Brazzaville P.O. Box 06, Congo.
Idah NdumbaPolio Eradication Program, Office of the Regional Director, World Health Organization, Regional Office for Africa, Brazzaville P.O. Box 06, Congo.
Priscilla MosokePolio Eradication Program, Office of the Regional Director, World Health Organization, Regional Office for Africa, Brazzaville P.O. Box 06, Congo.
Ousmane M DiopWorld Health Organization, 1211 Geneva, Switzerland.
John Kofi OdoomVirology Department, Noguchi Memorial Institute for Medical Research, College of Health Sciences, University of Ghana, Accra 00233, Ghana.
Martin FayeInstitute Pasteur, Dakar 12900, Senegal.ORCID 0000-0003-3207-6344
Gedi MohamedPolio Eradication Program, Office of the Regional Director, World Health Organization, Regional Office for Africa, Brazzaville P.O. Box 06, Congo.
Anfumbom KfutwahPolio Eradication Program, Office of the Regional Director, World Health Organization, Regional Office for Africa, Brazzaville P.O. Box 06, Congo.ORCID 0000-0002-1287-5934

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundSustaining progress toward polio eradication requires not only effective vaccination but also a resilient laboratory network capable of timely poliovirus detection, confirmation, and genetic characterization. In the WHO African region, the African polio laboratory network provides essential virological support for eradication efforts; however, persistent circulating Vaccine-derived Polioviruses (cVDPVs) outbreaks and increasing demands of genomic surveillance continue to challenge laboratory capacity. Despite its critical role, evidence describing the operational performance, adaptive capacity, and evolution of regional polio laboratory network remains limited. This study evaluates the performance and operational experience of the African polio laboratory network in 2025, highlighting contributions to poliovirus detection, genomic surveillance, quality assurance, and outbreak response, while sharing lessons to inform regional public health systems.

methodsA retrospective secondary data analysis was conducted using laboratory surveillance and outbreak databases, supplemented by reviews of programmatic reports. Data were cleaned and harmonized prior to analysis. Descriptive analyses were performed to assess laboratory workload, timeliness indicators, genomic capacity, quality assurance performance, and operational challenges. Qualitative review of programmatic documents was conducted to identify contextual factors influencing performance.

resultsIn 2025, 77,230 Acute Flaccid Paralysis (AFP) specimens were analyzed across 16 laboratories. Ninety-two percent of specimens met the timeliness target for virus isolation, and 94% met the target for PCR-ITD. Genomic sequencing confirmed 20 cVDPV outbreaks in 10 countries. The establishment of new sequencing laboratories in Uganda and Nigeria reduced turnaround times, and a 2025 expansion plan aimed to build sequencing capacity in 12 additional countries. All laboratories assessed in 2024 for virus isolation, PCR-ITD, and environmental surveillance exceeded quality assurance accreditation thresholds and were rated "Pass". The pilot implementation of Direct Detection Nanopore Sequencing (DDNS) techniques is expected to further strengthen genomic surveillance. Challenges remain, including stock out of essential supplies, uneven workloads, and infrastructure gaps.

conclusionsThe African polio laboratory network has demonstrated sustained capacity, adaptability, and innovation in supporting polio eradication activities in the WHO African region. This study provides evidence on the importance of strengthening laboratory systems, expanding genomic capacity, and maintaining quality assurance mechanisms to support the final phase of polio eradication and broader public health surveillance.

Indexed as

Africa polio laboratory networkcirculating vaccine-derived poliovirus (cVDPV)genomic surveillancelaboratory quality managementmolecular epidemiologypolio eradicationvaccines

Identifiers

PMID42797586
PMCPMC13611089

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.